Anurag Mehrotra, MD
Critical Care Medicine · Elk Grove Village, ILNPI 1033498472
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Intuitive Surgical at 46.3% of the total. Reporting peaked in 2022 at $1,880 and has fallen 68.1% since, to $600 in 2025.
Across 101 payments — averaging $45.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- GSK$400
- Pulmonx Corporation$297
- AstraZeneca$256
- Jazz Pharmaceuticals Inc.$207
- Johnson & Johnson$163
- plus $1K from 27 others
What the payments were for
- Travel & lodging$1,91842%
- Food & beverage$2,47954%
- Education$1724%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $2,126 |
| GSK | 25 | $400 |
| Pulmonx Corporation | 2 | $297 |
| AstraZeneca(2 entities) | 7 | $256 |
| Jazz Pharmaceuticals Inc. | 5 | $207 |
| Johnson & Johnson(2 entities) | 3 | $163 |
| Galvanize Therapeutics, Inc | 1 | $137 |
| Boehringer Ingelheim | 2 | $133 |
| Merck | 6 | $128 |
| Bayer | 1 | $93 |
| Insmed, Inc. | 3 | $61 |
| Novartis | 4 | $60 |
| AbbVie | 3 | $53 |
| Novo Nordisk | 1 | $50 |
| Sanofi | 2 | $47 |
| Lilly USA, LLC | 1 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $27 |
| Pinnacle Biologics, Inc | 1 | $26 |
| Genentech USA, Inc. | 2 | $25 |
| ERBE USA Inc | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| Davol Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $20 |
| Gilead | 1 | $19 |
| Amgen | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| United Therapeutics Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,589 in reported general payments places this provider in the 85th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $158,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $16,954 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,348 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,887 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,381 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $3,044 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $2,024 |
| Doxycycline Hyclate | 41 | $380 |
| Montelukast Sodium | 22 | $208 |
| Fluticasone Propionate | 20 | $173 |
| Prednisone | 39 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $400 | $167,896224 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $256 | $24,84140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Elk Grove Village
- Jessica JohnsonElk Grove Village$5K
- Rakesh VaddeElk Grove Village$4K
- Guy DuganElk Grove Village$3K
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.